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Abstract: Oncogenic metadherin is a key contributor to tumourigenesis with metadherin expression
and cytoplasmic localisation previously linked to poor survival. A number of reports have shown
metadherin localises specifically to nuclear speckles known to be rich in RNA-binding proteins
including the splicing proteins YTHDC1, Sam68 and T-STAR, that have been shown to select
alternative splice sites in mRNA of tumour-associated proteins including BRCA, MDM2 and VEGF.
Here we investigate the interaction and relationship between metadherin and the splice factors
YTHDC1, T-STAR and Sam68. Using a yeast two-hybrid assay and immunoprecipitation we show that
metadherin interacts with YTHDC1, Sam68 and T-STAR and demonstrate that T-STAR is significantly
overexpressed in prostate cancer tissue compared to benign prostate tissue. We also demonstrate
that metadherin influences splice site selection in a dose-dependent manner in CD44v5-luc minigene
reporter assays. Finally, we demonstrate that prostate cancer patients with higher metadherin
expression have greater expression of the CD44v5 exon. CD44v5 expression could be used to
discriminate patients with poor outcomes following radical prostatectomy. In this work we show
for the first time that metadherin interacts with, and modulates, the function of key components of
splicing associated with cancer development and progression.
Keywords: alternative splicing; CD44; YTHDC1; SAM68; prostate cancer
1. Introduction
Metadherin, also known as LYRIC/AEG1, plays a pivotal role in cancer and is reported to have many
functions and subcellular localisations including mRNA binding in the endoplasmic reticulum (ER).
Additionally, some have suggested nuclear roles such as the inhibition of apoptosis via FOXO3a and
FOXO1 in endocrine cancers, the regulation of c-myc expression through the transcriptional repressor
promyelocytic leukemia zinc finger (PLZF) and the modulation of cell cycle progression through
BRCA2-and CDKN1A-interacting protein a (BCCIPa) [1–6]. During prostate cancer development,
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metadherin has been shown to translocate from the nucleus to the cytoplasm, indicating that an
important nuclear role of metadherin is lost during prostate tumourigenesis [7,8].
Alternative splicing of pre-mRNA is a major driver of protein diversity and affects more than 95% of
multi-exonic coding human genes [9]. Upregulation of endogenous alternatively spliced tumourigenic
variants is frequently observed in many cancers such as the proangiogenic splice variant of vascular
endothelial growth factor (VEGF165), an epithelial-mesenchymal transition-inducing isoform of Rac1
(Rac1b), and the cancer-initiating form of protein kinase C (PKCβII) [10–13]
YTHDC1 is a ubiquitously expressed nuclear protein involved in splice site selection that localises
to YT bodies; dynamic compartments, which first appear at the beginning of S-phase in the cell
cycle and disperse during mitosis [14]. These sub-nuclear speckles co-localise with several known
spliceosome proteins including SRSF2 [14–16]. Using minigene reporter assays YTHDC1 has been
shown to modulate mRNA splice site selection in a concentration-dependent manner [17,18]. More
recently, the ability of YTHDC1 to splice endogenous transcripts has been demonstrated for vascular
endothelial growth factor (VEGF), breast cancer 1 (BRCA1) and the progesterone receptor (PGR) [19,20].
Sam68 is associated with many hallmarks of cancer including epithelial-mesenchymal transition via
stabilisation of the splicing factor SF2/ASF, cell cycle progression through Cyclin D1b, inhibition of
apoptosis via BCL-X, cell migration through the cell surface protein CD44, and enhanced cell survival
in response to DNA damage [21–24]. Sam68, the related protein T-STAR and YTHDC1 all localise to
Sam68 nuclear bodies which traffic mRNAs through the nucleus [25–28].
Here we describe a novel function for nuclear metadherin as a modulator of pre-mRNA processing.
We show that metadherin modulates alternative splicing via interactions with known splicing factors
YTHDC1, Sam68 and T-STAR, potentially revealing novel tumour biomarkers and therapeutic targets.
2. Results
2.1. Metadherin Interacts with Splicing Protein Ythdc1
A human placental cDNA library and the metadherin C-terminal domain (CTD, amino acids
(aa) 73–582) were used in a yeast two-hybrid assay, which identified aa54–355 of YTHDC1 as a
metadherin-interacting domain (Figure 1A,B). The interaction between endogenous YTHDC1 and
metadherin was confirmed in mammalian cells by immunoprecipitation using two anti-metadherin
antibodies: AK (IP-AK) or SS (IP-SS) [29] (Figure 1C).
Metadherin has been associated with several sub-cellular localisations including nuclear speckles
associated with FOXO3a and PLZF [4,5]. Using confocal microscopy, we showed that nuclear
wt-metadherin co-localised completely with YTHDC1 in sub-nuclear speckles, most likely YT
bodies (Figure 1D). When wt-metadherin was over-expressed, YTHDC1 retained its previously
described co-localisation with the well-characterised splice factor SRSF2, suggesting that YTHDC1
may associate with spliceosomal proteins and co-localise with metadherin within YT bodies (Figure S1,
Supplementary Materials) [14].
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Figure 1. Metadherin interacts with YTHDC1 in the nucleus. (A) Schematic representation of 
metadherin (upper panel) and YTHDC1 constructs (lower panel). Lysine-rich domains (KRD) of 
metadherin shown in grey rectangles (top), and glutamine rich domain (QRD) of YTHDC1 shown in 
grey hexagon (bottom). (B) Yeast two-hybrid assay using pLexA-DIR-metadherin-aa73–582 (C-
terminal domain (CTD)-metadherin) as bait and a human placental cDNA library. β-Galactosidase 
assay confirms interaction between YTHDC1 and metadherin, YTHDC1 well circled in black, adjacent 
wells show alternate targets which were all negative. (C) Endogenous metadherin was 
immunoprecipitated using two antibodies against a central epitope (IP-AK) and C-terminal epitope 
(IP-SS) with metadherin from 1 mg of COS7 protein lysate. Input is 10 µg protein lysate, sheep IgG 
was used as control. Western blots were probed for YTHDC1 and metadherin (SS). Blots were 
visualised with enhanced chemiluminescent luminol-based (ECL) substrate plus or, when the signal 
exceeded the dynamic range of film, using 3,3'-Diaminobenzidine (DAB). (D) COS7 cells were fixed 
in methanol, probed with an anti-YTHDC1 (red) and anti-metadherin (green) antibodies, and 
mounted with DAPI (blue). White arrows show nuclear localization of the target protein, blue arrows 
indicate cytoplasmic localization. Images were obtained using a Nikon Eclipse confocal microscope 
using a ×100 objective. Scale bars represent 10 µm. 
2.2 Sam68-Associated Protein T-Star is Androgen-Regulated and Overexpressed in Prostate Cancer 
The known spliceosome protein, Sam68, is reported to interact with the androgen receptor (AR) 
and modulate the splicing of the receptor itself as well as AR targets [30,31].These reports led us to 
investigate the androgen regulation of proteins associated with alternative splicing using expression 
data generated from the LNCaP cell line treated with synthetic androgen (R1881) or vehicle control 
(EtOH). Results indicated androgen regulation of the Sam68-related protein T-STAR, however, no 
androgen regulation was observed for probes against metadherin, SAM68 or YTHDC1 (Figure 2A 
and Figure S2, Supplementary Materials). 
The STAR proteins are splicing factors with well characterised roles in spermatogenesis, 
adipogenesis, neuronal development and tumourigenesis [30,32–34]. Using immunohistochemistry 
we established the over expression of T-STAR in prostate tumourigenesis showing that nuclear T-
STAR expression was low in benign tissue and upregulated in tumour tissue based on a two-tailed 
Mann–Whitney test (p < 0.0001) [35] (Figures 2B and 2C). Interestingly, T-STAR expression also 
associated with Likert score, an ordinal score (ranging from 1–5) that denotes the likelihood of a 
significant tumour on magnetic resonance imaging (MRI, Figure 2C), but was not significantly 
associated with Gleason Grade despite a trend towards higher expression with increasing Gleason 
Figure 1. Metadherin interacts with YTHDC1 in the nucleus. (A) Schematic representation of
metadherin (upper panel) and YTHDC1 constructs (lower panel). Lysine-rich domains (KRD) of
metadherin shown in grey rectangles (top), and glutamine rich domain (QRD) of YTHDC1 shown in
grey hexagon (bottom). (B) Yeast two-hybrid assay using pLexA-DIR-metadherin-aa73–582 (C-terminal
domain (CTD)-metadherin) as bait and a human placental cDNA library. β-Galactosidase assay
confirms interaction between YTHDC1 and metadherin, YTHDC1 well circled in black, adjacent wells
show alternate targets which were all negative. (C) Endogenous metadherin was immunoprecipitated
using two antibodies against a central epitope (IP-AK) and C-terminal epitope (IP-SS) with metadherin
from 1 mg of COS7 protein lysate. Input is 10 µg protein lysate, sheep IgG was used as control.
Western blots were probed for YTHDC1 and metadherin (SS). Blots were visualised with enhanced
chemiluminescent luminol-based (ECL) substrate plus or, when the signal exceeded the dynamic range
of film, using 3,3’-Diaminobenzidine (DAB). (D) COS7 cells were fixed in methanol, probed with an
anti-YTHDC1 (red) and anti-metadherin (green) antibodies, and mounted with DAPI (blue). White
arrows show nuclear localization of the target protein, blue arrows indicate cytoplasmic localization.
Images were obtained using a Nikon Eclipse confocal microscope using a ×100 objective. Scale bars
represent 10 µm.
2.2. Sam68-Associated Protein T-Star is Androgen-Regulated and Overexpressed in Prostate Cancer
The known spliceosome protein, Sam68, is reported to interact with the androgen receptor (AR)
and modulate the splicing of the receptor itself as well as AR targets [30,31].These reports led us to
investigate the androgen regulation of proteins associated with alternative splicing using expression
data generated from the LNCaP cell line treated with synthetic androgen (R1881) or vehicle control
(EtOH). Results indicated androgen regulation of the Sam68-related protein T-STAR, however, no
androgen regulation was observed for probes against metadherin, SAM68 or YTHDC1 (Figure 2A and
Figure S2, Supplementary Materials).
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Figure 2. T-STAR is overexpressed in prostate cancer. (A) Androgen regulation of T-STAR 
determined by expression analysis of LNCaP cell lines treated with synthetic androgen (open circles) 
or vehicle control (filled circles) over 24hrs. ACF = autocorrelation function. (B) Examples of 
immunohistochemistry (IHC) of T-STAR showing benign (left) and tumour (right) tissue. Staining is 
shown in brown with nuclei shown in blue. (C) Staining was analysed by h-score and analysed based 
on pathology (left), Gleason score (centre) and Likert score (right). Dots represent individual patients, 
whiskers extend to the minimum and maximum data points, the boxes represent data from first to 
third quartile, and the horizontal line represents the mean. Significance was analysed using two-tailed 
Mann–Whitney test. 
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To determine if metadherin interacts with these other splicing complex proteins we 
immunoprecipitated (IP) metadherin from LNCaP whole cell lysates and detected interactions 
between metadherin and both Sam68 and T-STAR (Figure 3B). Using an anti-SAM68 antibody, 
reciprocal interactions could also be detected between T-STAR, metadherin and Sam68 (Figure 3C). 
The authors noted that the reciprocal IP of the band for metadherin was slightly obscured by the 
signal from the 50kDa light chain band below therefore was highlighted (Figure 3C). Additionally, 
the bands detected in IP lane run slightly lower than input lane due to the increased concentration of 
salts and detergent in the radioimmunoprecipitation assay (RIPA) buffer. These results confirmed 
the existence of a complex containing metadherin and other, well characterised, splicing proteins and 
taken with our localisation data it suggests these interactions most likely occur in the nucleus. 
Figure 2. T-STAR is overexpressed in prostate cancer. (A) Androgen regulation of T-STAR determined by
expression analysis of LNCaP cell lines treated with synthetic androgen (open circles) or vehicle control
(filled circles) over 24hrs. ACF = autocorrelation function. (B) Examples of immunohistochemistry
(IHC) of T-STAR showing benign (left) and tumour (right) tissue. Staining is shown in brown with
nuclei shown in blue. (C) Staining was analysed by h-score and analysed based on pathology (left),
Gleason score (centre) and Likert score (right). Dots represent individual patients, whiskers extend to
the minimum and maximum data points, the boxes represent data from first to third quartile, and the
horizontal line represents the mean. Significance was analysed using two-tailed Mann–Whitney test.
The STAR proteins are splicing factors with well characterised roles in spermatogenesis,
adipogenesis, neuronal development and tumourigenesis [30,32–34]. Using immunohistochemistry
we established the over expression of T-STAR in prostate tu ourigenesis showing that nuclear
T-STAR expression was low in benign tissue and upregulated in tumour tissue based on a two-tailed
Mann–Whitney test (p < 0.0001) [35] (Figure 2B,C). Interestingly, T-STAR expression also associated
with Likert score, an ordinal score (ranging from 1–5) that denotes the likelihood of a significant tumour
on magnetic resonance imaging (MRI, Figure 2C), but was not significantly associated with Gleason
Grade despite a trend towards higher expression with increasing Gleason Grade (p = 0.15). Taken
together these results suggest a link between splicing proteins and tumourigenesis.
As we saw altered expression of T-STAR in prostate cancer, we used a panel of prostate cell lines
to examine the protein expression of alternative splicing components, specifically Sam68, T-STAR,
YTHDC1 and metadherin (Figure 3A). All of the splice factors examined were detected in LNCaP
cells and the LNCaP-derived prostate cancer cell lines C4-2 and C4-2B, but not in the benign prostate
cell line PNT1a supporting a role in tumourigenesis. We also failed to detect Sam68 in the androgen
independent PC3 cell line.
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Figure 3. T-STAR interacts with metadherin and is overexpressed in prostate cancer. (A) Expression 
of YTHDC1, Sam68, T-STAR and metadherin were examined in protein lysates from prostate cancer 
cell lines PNT1a, LNCaP, C4-2, C4-2B and PC3. (B) Endogenous metadherin was immunoprecipitated 
from 1mg LNCaP protein lysate with 10µg protein lysate used as input and rabbit IgG as a negative 
control. (C) Endogenous SAM68 was immunoprecipitated from 1 mg LNCaP protein lysate. 10 µg 
protein lysate was used as input, rabbit IgG as a negative control. White arrow indicates the band 
corresponding to metadherin. 
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As we have shown that metadherin interacts with alternative splicing proteins we investigated 
if metadherin had a functional effect on splicing by assessing the inclusion of exon v5 in the CD44v5-
luc minigene (Figure 4A, left) [5]. Previous reports have shown the larger C-terminal domain of 
metadherin interacts with the transcriptional repressor PLZF, and the N-terminal domain interacts 
with the microtubule organising protein BCCIPα so we used both wild-type (wt) and domain 
constructs of metadherin to assess their ability to influence splicing activity [5,6]. Firstly we examined 
the ability of metadherin alone on its ability to influence CD44v5-luc minigene splicing. Both the wt- 
and the C-terminal domain (CTD)-metadherin constructs could significantly activate CD44v5-luc 
splicing (p < 0.01) resulting in an increase in luciferase detection whereas N-terminal domain (NTD)-
metadherin tended to reduce exon inclusion (Figure 4B). These data support a role for metadherin in 
alternative splicing and build upon previous results implicating metadherin in RNA binding in the 
endoplasmic reticulum [1]. 
YTHDC1 is known to repress exon inclusion of the CD44v5-luc minigene[17,18]. To assess the 
impact of YTHDC1 and metadherin together on alternative splicing, the metadherin constructs were 
overexpressed alongside YTHDC1 in mammalian cells transfected with the CD44v5-luc minigene 
(Figure 4C). As expected YTHDC1 caused a significant reduction in exon skipping compared to the 
CD44v5-luc reporter gene alone confirming ability of YTHDC1 to recognise alternative splice sites (p 
< 0.04) (Figure 4B) [17]. The addition of wt-metadherin resulted in an increase in exon inclusion that 
abolished the exon skipping effect of YTHDC1 (Figure 4C). CTD-metadherin was also able to induce 
exon inclusion, to levels equivalent to baseline. No effect was observed with NTD-metadherin. This 
indicates that metadherin may regulate the effect of YTHDC1 in alternative splicing. 
Figure 3. T-STAR interacts with metadherin and is overexpressed in prostate cancer. (A) Expression
of YTHDC1, Sam68, T-STAR and metadherin were examined in protein lysates from prostate cancer
cell lines PNT1a, LNCaP, C4-2, C4-2B and PC3. (B) Endogenous metadherin was immunoprecipitated
from 1mg LNCaP protein lysate with 10µg protein lysate used as input and rabbit IgG as a negative
control. (C) Endogenous SAM68 was im unopreci itated from 1 mg LNCaP protein lysate. 10 µg
protein lysate was used as input, rabbit IgG as a negati trol. White arrow indica es the band
corresponding to metadherin.
2.3. Metadherin Directly In racts with Splicing Complex Proteins Sam68 and T-Star
To determine if metadherin interac s with thes o h r splicing complex proteins we
immunoprecipitated (IP) metadherin from LNCaP whole cell lysates and detected interactions between
metadherin and both Sam68 and T-STAR (Figure 3B). Using an anti-SAM68 antibody, reciprocal
interactions could also be detected between T-STAR, metadherin and Sam68 (Figure 3C). The authors
noted that the reciprocal IP of the band for metadherin was slightly obscured by the signal from the
50kDa light chain band below therefore was highlighted (Figure 3C). Additionally, the bands detected
in IP lane run slightly lower than input lane due to the increased concentration of salts and detergent in
the radioimmunoprecipitation assay (RIPA) buffer. These results confirmed the existence of a complex
containing metadherin and oth r, well haracter sed, splicing proteins and t ken with our localisation
data it suggests these interactions most likely occ r in the nucleus.
2.4. Metadherin Attenuates the Effect of Ythdc1 on Cd44v5-Luc Splicing
As we have shown that metadherin interacts with alternative splicing proteins we investigated if
metadherin had a functional effect on splicing by assessing the inclusion of exon v5 in the CD44v5-luc
minigene (Figure 4A, left) [5]. Previous reports have shown the larger C-terminal domain of metadherin
interacts with the transcriptional repressor PLZF, and the N-terminal domain int racts with the microtubule
organising pro ein BCCIPα so we used both wild-typ (wt) and domain constructs of meta herin to
assess their ability to influence splicing activity [5,6]. Firstly we examined the ability of metadherin
alone on its ability to influence CD44v5-luc minigene splicing. Both the wt- and the C-terminal domain
(CTD)-metadherin constructs could significantly activate CD44v5-luc splicing (p < 0.01) resulting in an
increase in luciferase detection whereas N-terminal domain (NTD)-metadherin tended to reduce exon
inclusion (Figure 4B). These data support a role for metadherin in alternative splicing and build upon
previous results implicating metadherin in RNA binding in the endoplasmic reticulum [1].
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Figure 4. Metadherin promotes exon inclusion during splicing. (A) Left: Schematic representation of 
CD44v5-luc construct with v5 exon inclusion (top) and exclusion (bottom) Right: Schematic 
representation of metadherin constructs with wild-type (WT)-metadherin (top), N-terminal domain-
metadherin (NTD-metadherim) (middle) and C-terminal domain metadherin (CTD-metadherin) 
(bottom) (B). COS7 cells were transfected with CD44v5-luc and increasing concentrations of the 
metadherin constructs: WT-metadherin (dark grey bars), NTD-metadherin (empty bars), CTD-
Figure 4. Metadherin promotes exon inclusion during splicing. (A) Left: Schematic representation of
CD44v5-luc construct with v5 exon inclusion (top) and exclusion (bottom) Right: Schematic representation
of metadherin constructs with wild-type (WT)-metadherin (top), N-terminal domain-metadherin
(NTD-metadherim) (middle) and C-terminal domain metadherin (CTD-metadherin) (bottom) (B). COS7
cells were transfected with CD44v5-luc and increasing concentrations of the metadherin constructs:
WT-metadherin (dark grey bars), NTD-metadherin (empty bars), CTD-metadherin (light grey bars). BOS
β-galactosidase plasmid was also transfected to control for transfection efficiency. Luciferase activity
normalised using a β-galactosidase activity and reported relative to the reporter alone (*). (C) COS7
cells were transfected with CD44v5-luc, BOS-β-galactosidase, YTHDC1 and increasing concentrations
of the metadherin constructs and assayed as in (B). (D) COS7 cells were transfected with CD44v5-luc,
BOS-β-galactosidase, YTHDC1, Sam68 and increasing concentrations of the metadherin constructs, grown
and assayed as in (B). Schematics left of plots show exon exclusion represented by low relative luciferase
and exon inclusion with high relative luciferase. Grey triangle represents increase in exon inclusion.
P-values were calculated using a Student’s two-tailed t-test. **/*** indicate significant differences compared
to bars marked “#”.
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YTHDC1 is known to repress exon inclusion of the CD44v5-luc minigene [17,18]. To assess the
impact of YTHDC1 and metadherin together on alternative splicing, the metadherin constructs were
overexpressed alongside YTHDC1 in mammalian cells transfected with the CD44v5-luc minigene
(Figure 4C). As expected YTHDC1 caused a significant reduction in exon skipping compared to the
CD44v5-luc reporter gene alone confirming ability of YTHDC1 to recognise alternative splice sites
(p < 0.04) (Figure 4B) [17]. The addition of wt-metadherin resulted in an increase in exon inclusion that
abolished the exon skipping effect of YTHDC1 (Figure 4C). CTD-metadherin was also able to induce
exon inclusion, to levels equivalent to baseline. No effect was observed with NTD-metadherin. This
indicates that metadherin may regulate the effect of YTHDC1 in alternative splicing.
Sam68 has previously been shown to increase exon inclusion and as expected, the addition of
Sam68 increased CD44v5 exon inclusion in a dose-dependent manner up to 75ng/well (Figure S4A,
Supplementary Materials) [21]. As shown by Hartmann et al. YTHDC1 induced exon skipping
even in the presence of Sam68 (Figure 4D) [17]. However, the addition of either wt-metadherin or
CTD-metadherin resulted in an increase in exon inclusion in a dose-dependent manner (Figure 4D).
Once again NTD-metadherin had no effect on the ability of YTHDC1 to exclude the V5 exon suggesting
that the C-terminal domain of metadherin, also contained with the wt-metadherin construct is essential
for its interaction with YTHDC1 and its role in alternative splicing.
Finally, our evidence suggested a relationship between metadherin and the splicing of CD44
in vitro, however, it remained to be seen if a relationship existed in an endogenous context. To this end,
we attempted to further confirm this in a patient cohort. The Cancer Genome Atlas (TCGA) prostate
adenocarcinoma (PRAD) cohort was used to compare CD44v5 exon expression between patients with
either high or low metadherin expression (separated by median expression). There was a significant
increase in the expression levels of CD44v5 mRNA between patients with low and high metadherin
expression (p = 0.002), concordant with our observation that increased metadherin results in greater
inclusion of the CD44v5 exon leading to greater expression (Figure 5A). Another interpretation of
this result may be that metadherin and CD44 are co-expressed leading to this pattern of expression.
Comparing metadherin mRNA expression to that of full-length CD44 did reveal a weak but significant
difference, however, in the opposite direction (p = 0.015) indicating that there was a specific effect
on the inclusion of exon v5 in tumours with high metadherin expression not explained by simple
co-expression (Figure 5B). To investigate the potential clinical significance of this relationship, we
compared the disease-free survival of patients with high and low CD44v5 expression (expression was
discretized into high and low expressers using the MaxStat R package). The comparison found a
significant difference in disease-free survival between low and high expressers (p = 0.031) with median
disease-free survival for low CD44v5 patients being 82.3 months and the median for high CD44v5
expressers, not reached (Figure 5C).
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Figure 5. Increased metadherin expression is associated with increased CD44v5 exon expression and 
altered disease free survival. (A) CD44v5 mRNA expression levels between The Cancer Genome Atlas 
(TCGA) prostate adenocarcinoma (PRAD) patients separated by median metadherin expression. (B) 
Figure 5. Increased metadherin expression is associated with increased CD44v5 exon expression and
altered disease free survival. (A) CD44v5 mRNA expression levels between The Cancer Genome
Atlas (TCGA) prostate adenocarcinoma (PRAD) patients separated by median metadherin expression.
(B) Overall CD44 mRNA expression between patients separated by median metadherin expression
(C) Kaplan-Meier showing disease-free survival time in patients segregated by CD44v5 mRNA
expression. P-values were calculated using a Student’s two-tailed t-test and a log-rank test respectively.
3. Discussion
Metadherin has previously been shown to regulate processes important in cancer such as mRNA
binding within the ER, regulation of apoptosis and regulation of c-myc expression [1–6]. Here, for the
first time, we demonstrated a novel nuclear role for metadherin, where it binds to YTHDC1 and
co-localise in sub-nuclear speckles to regulate splicing. Our observation is consistent with previous
studies in which, metadherin has been shown to localise to nuclear speckles and to fine-tune many
nuclear functions, including the regulation of expression of tumour promotor FOXO3a, the attenuation
of promyelocytic leukaemia zinc finger protein (PLZF)-mediated transcriptional repression and the
direct modulation of tumour-associated BCCIPα degradation [3–6]. Additionally, it has been described
that nuclear translocalisation of metadherin occurs upon stimulation with TNF-α [36]. However, this
is the first time metadherin has been shown to be associated with splicing machinery.
Other splicing proteins such as Sam68 have been demonstrated to interact with the AR which
modulates key genes in this process [31]. Androgens play a key part in the development and progression
of prostate cancer. Here, we demonstrated that Sam68-associated protein T-STAR expression was
dependent on stimulation from synthetic R1881 in LNCaP cells. Moreover, the expression of metadherin
and splisosomal proteins YTHDC1, Sam68 and T-STAR were all absent in benign prostate cell-lines
and expressed highly in tumourigenic lines further suggesting a link between splicing machinery and
tumuorigenesis. To this end, we also examined the expression of T-STAR in prostate cancer biopsy
cores and adjacent benign tissue from a total of 249 men from the prostate imaging compared to
transperineal ultrasound-guided biopsy for significant prostate cancer risk evaluation (PICTURE)
trial. T-STAR expression was significantly upregulated in tumour cores compared to adjacent benign
tissue. This observation, while intriguing, somewhat contradicts our study in LNCaP cells showing
a strong negative androgen regulation. As our experimental model only looked at R1881 response
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up to 24 hours, it may be that long-term compensatory mechanisms act to reverse this change.
Alternatively, the high variation of T-STAR expression within our cohort may suggest that some
patients have undergone regulatory changes in the machinery regulating androgen signalling, although
this is purely speculative. T-STAR expression has previously been shown to be altered in breast
cancer and correlated with estrogen receptor negativity and HER2 status suggesting alternative
signalling pathways regulating T-STAR may well exist [37]. More simply, T-STAR mRNA levels
may not correlate well with T-STAR protein expression. Our observation that T-STAR becomes
overexpressed in cancer complements work on closely related STAR family member Sam68, shown
to interact with T-STAR, which has previously been shown to have oncogenic functions and is
associated with poor prognosis in several cancers [22,23,38]. Other splicing factors such as proline- and
glutamine-rich/non-POU domain-containing octamer-binding protein (PSF/NONO) and heterogeneous
nuclear ribonucleoprotein (HNRNP) have also been shown to become dysregulated in prostate cancer
where they become key driving forces for progression [39].
Additionally and unexpectedly, we also found that increased T-STAR expression also significantly
associated with higher Likert tumours. Likert score has been demonstrated to correlate with Gleason
grade [40]. T-STAR weakly associated with Gleason grade, however, as this association was not
significant it may be that T-STAR expression correlates more highly with another unknown tumour
feature detected by multi-parametric MRI. This moderate association is noteworthy, as few studies
have been carried out to determine which biological processes determine MRI visibility and those that
have often describe genes associated with cell growth as well as AR signalling to be upregulated in
MRI visible lesions [41,42].
Given our observation that metadherin interacts with splicing protein YTHDC1, we clarified if
there was also potential interaction with alternative splicing proteins T-STAR and Sam68. Our results
demonstrated that there was a clear interaction between metadherin and all four splicing proteins
cementing the assumption that metadherin associates with splicing machinery.
Next, we looked at how metadherin influenced the splicing in an experimental system using a
minigene derived from the human CD44 gene. CD44 is highly studied in human malignancy and
specific splice-variants of CD44 have been causally related to metastatic behaviour in a variety of
carcinomas [43]. CD44 has been suggested as a target for immunotherapy or as a treatment, using
antibodies conjugated to anti-tumour agents [43]. We discovered that both WT and CTD-metadherin
could significantly activate CD44v5-luc splicing. Furthermore, we found that YTHDC1, previously
demonstrated to repress exon inclusion in the same system, could be overridden through the addition
of WT-metadherin, suggesting that the interaction between metadherin and YTHDC1 may sequester
YTHDC1 away from RNA binding sites, thus reducing any repressive effect. Alternatively, metadherin
could repress YTHDC1 exon skipping by recruiting repressor proteins, similar to its previous nuclear
role with PLZF [5]. Interestingly, this override could not be achieved through the addition of Sam68 as
previously found. These effects were only present with either WT or CTD-metadherin in opposed
to NTD-metadherin indicating that the C-terminal domain is crucial for metadherin’s regulation of
alternative splicing.
Finally, we attempted to confirm our observations in a clinical context, finding increased CD44v5
expression in prostate cancer patients who have high metadherin expression. This supported our
in vitro assay findings, suggesting increased inclusion of the CD44v5 exon in patients with higher
metadherin; this was despite having an overall negative correlation with full-length CD44 mRNA.
Furthermore, this relationship may have some clinical significance as reduced CD44v5 expression was
associated with reduced disease-free survival following radical prostatectomy. These findings may
be of particular relevance in cancer therapy, where metadherin has recently been highlighted as an
important therapeutic target [44].
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4. Materials and Methods
4.1. Cell Culture
All cells were purchased from ATCC. COS-7 cells were routinely cultured in Dulbecco’s modified
Eagle’s media (DMEM). PNT1a, LNCaP, C4-2 and C4-2B cells were routinely cultured in Roswell Park
Memorial Institute (RPMI) 1640 media. All media was supplemented with 10% fetal bovine serum.
4.2. Plasmids
Wild-type (wt) metadherin(metadherin-aa1-582) and the C-terminal domain (metadherin-aa73-582)
were cloned from T7-wt-metadherin [45] into mammalian pSG5 using BamH1 and EcoR1 restriction
sites. The N-terminal domain (metadherin-aa1-73) was cloned into the CMV-Myc vector using EcoRI
and NotI. CD44v5-minigene plasmid was a kind gift from Harald König (Institute of Toxicology and
Genetics, Germany) [46]. YTHDC1-B constructs were kindly provided by Stefan Stamm (University of
Kentucky, USA) [17]. Sam68 was a gift from Tetsu Akiyama (University of Tokyo, Japan) [47].
4.3. CD44 Minigene Assays
CD44v5-minigene plasmid was transfected into cells alongside wt-metadherin, N-terminal
metadherin or C-terminal metadherin and a BOS β-galactosidase plasmid to control for transfection
efficiency (25 ng/well) [48]. Empty pSG5 vector was used to equalise the amount of DNA transfected.
After 48 hours cells were harvested on ice for 15 minutes using reporter lysis buffer (50 mM Tris HCl
pH 7.2, 0.1% Tween-20, 1 mM CaCl2, 1 mM MgCl2). Luciferase activity was measured using the Luclite
luciferase assay kit (Packard Biosciences). Results were normalised using a β-galactosidase activity
measured with a Galacton Galactolite assay kit (Tropix). All assays were completed on at least three
separate occasions. P-values were calculated using a Student’s two-tailed t-test.
4.4. Yeast Two-Hybrid Assay
A yeast two-hybrid assay was performed by Dualsystems Biotech AG, Zurich, Switzerland using
pLexA-DIR-metadherin-aa73-582 as bait and a human placental cDNA library as described [5].
4.5. Cell lysates, Western Blotting and Immunoprecipitation
All Western blotting procedures were performed as described [49]. Membranes
were incubated with primary antibody; anti-metadherin antibodies AK (recognises residues
197SHREKRQQRKRDKV210) and SS (recognises 568SPKQIKKKKKARRET582), 1:2000 supplied by
Heidi Sutherland (MRC Human Genetics Unit, UK) [45], anti-YTHDC1 1:3000 supplied by Stefan
Stamm [17], anti-KHDRBS3 (tSTAR) 1:500 (HPA000275, Sigma Aldrich), anti-Sam68 1:1000 (ab109197,
Abcam) and anti-β-actin 1:10,000 (ab6276, Abcam). All secondary antibodies (DakoCytomation) were
used at 1:1000. Proteins were detected with ECL-Plus (GE Healthcare) and where they exceeded the
dynamic range of film diaminobenzidine (Vector Laboratories, UK) was used. Immunoprecipitation
was performed at 4 ◦C using the method previously described [7].
4.6. Confocal Microscopy
Cells were grown on glass coverslips in 24-well plates, transfected with 1 µg of DNA per 6 wells
of a 24-well plate using FuGENE6. After 48 hours cells were fixed stained and mounted as previously
described [7]. Images were taken using a Zeiss Meta 510 confocal microscope using a 63x objective. All
scale bars represent 10 µM.
4.7. Tissue Microarray and Immunohistochemistry
All immunohistochemistry was performed using a Bondmax Autostainer (Leica) using KHDRBS3
(T-STAR) antibody (1:400, HPA000275, Sigma Aldrich) and citrate buffer pH 6.0 (ER1) for antigen
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retrieval. The specificity of antibody staining was validated using qPCR and immunohistochemistry
of a formalin-fixed paraffin-embedded COS7 cell pellets transiently transfected with siRNA against
T-STAR or a non-targeting control (Figure S3, Supplementary Materials). Loss of staining in the specific
cellular compartment in up to 50% of cells in the siRNA group alongside a significant reduction in
mRNA was considered specific.
Tissue microarrays constructed from needle biopsies collected from the PICTURE trial consisted
of paired tissue from 249 men as previous described [35]. Slides were scanned using a NanoZoomer-SQ
digital slide scanner (Hamamatsy Photonics, Japan) and each individual core was assessed for the
presence of cancer by a trained uro-pathologist (AF) as well as being scored by two independent
scorers (HW and VS) without prior knowledge to clinical data. Cores were scored using the h-score
method where an intensity score (0 = none, 1 = weak, 2 = intermediate, 3 = strong) was multiplied by
the percentage of epithelial cells with that score; h-score = (% no staining × 0) + (% weak staining × 1)
+ (% moderate staining × 2) + (% strong staining × 3) [50]. Informed consent was obtained for all
patients prior to the creation of the tissue microarray (TMA).
4.8. Statistics and Data Analysis
All statistical analysis was performed using either IBM SPSS version 24 software or the R
statistical environment. The CD44 exon-specific expression from the TCGA PRAD provisional
cohort was downloaded from TSVdb: a web-tool for TCGA splicing variants analysis. Available:
http://www.tsvdb.com. This data was matched with clinical data downloaded from the broad firehose,
available: https://gdac.broadinstitute.org/. Discretization of expression for survival analysis and
survival analysis was performed using the MaxStat and survminer R packages respectively.
5. Conclusions
Our results support research that splicing machinery components may become dysregulated in
prostate cancer and may do so in response to androgen signaling. They also suggest for the first time,
a potentially important role for metadherin, a known oncogene, in regulating alternative splicing in
genes with potential clinical significance in prostate cancer. Recent literature has identified metadherin
as a potentially valuable therapeutic target, therefore, elucidating key interaction interacting proteins
and modulators of metadherin’s function may also have future relevance to targeted therapies.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/9/1233/s1:
Figure S1. YTHDC1 co-localises with the splicing factor SRSF2. Figure S2: Androgen regulation of metadherin,
Sam68 and YTHDC1. Figure S3: T-STAR knockdown in COS7 cells. Figure S4: Defining the parameters for the
CD44v5-luc assay.
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